Venture capital firm W Health Ventures has announced the initial close of its second fund, Fund II, at Rs 550 crore, while setting a final target of Rs 630 crore. With this milestone, the firm is strengthening its commitment to building and scaling healthcare companies across India and the US–India corridor by leveraging its proven company-building model.
Through this fund, W Health Ventures will actively support the creation, incubation, and expansion of healthcare startups that address critical gaps in clinical delivery and healthcare operations. Moreover, the firm will focus on developing technology-first, scalable healthcare solutions that can deliver long-term impact.
Commenting on the fund’s strategy, Managing Partner Pankaj Jethwani explained that the firm co-founds companies from inception, enabling founders to tackle underserved areas with deep operational involvement. “Our Fund I portfolio has already impacted 25 million lives globally, and we aim to scale this to a billion lives over the next two decades,” he added. In line with this vision, Fund II will incubate 8–10 new companies, deploying Rs 30–50 crore per venture.
As part of its early execution, W Health Ventures has already launched Everhope Oncology, a national oncology platform co-founded with Narayana Health, as the first company under Fund II. At the same time, the firm is incubating a stealth venture that is enabling US-based psychiatry clinics to expand access to advanced treatments for treatment-resistant depression.
Meanwhile, Partner Gaurav Porwal emphasised the firm’s strong backing from its limited partners and reaffirmed its focus on building foundational healthcare companies. He highlighted that W Health Ventures continues to prioritise high-impact sectors, including oncology, preventive healthcare, geriatrics, and chronic care management, where long-term innovation remains critical.
With the successful initial close of Fund II, W Health Ventures is reinforcing its position as a leading healthcare company builder, focused on scalable innovation and cross-border impact.
